Issue Date: April 11, 2016 | Web Date: April 6, 2016
Tax rules kill Pfizer-Allergan merger deal
Pfizer and Allergan have dropped their plan to merge after the issuance of proposed rules by the U.S. Department of Treasury. The new rules likely would have prevented an “inversion,” in which U.S.-based Pfizer was to reduce its tax rate by buying Ireland’s Allergan and shifting its headquarters overseas.
With a $160 billion price tag, the merger would have created the world’s largest pharmaceutical company with about $64 billion . . .
To view the rest of this content, please log in with your ACS ID.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society